EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023

Description: EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023

Summary

Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), is a condition characterized by difficulty breathing, shortness of breath, wheezing, chest tightness, and other respiratory symptoms that progress over time. The disease is often caused by smoking; however, long-term exposure to other lung irritants, such as pollution, smoke from vehicle emissions and power stations, chemical fumes, and dust, can also lead to the development of COPD. COPD is also a significant cause of morbidity and mortality, and the World Health Organization (WHO) predicts that it will be the third leading cause of death in the world by 2030.

In the 8MM, GlobalData epidemiologists forecast that the total prevalent cases of COPD will increase from 64,229,605 cases in 2013 to 73,794,089 cases in 2023 at an Annual Growth Rate (AGR) of 1.49%. GlobalData epidemiologists also forecast that the diagnosed prevalent cases of COPD will increase from 18,920,845 cases in 2013 to 21,789,454 cases in 2023 at an AGR of 1.52%. In the 8MM in 2013, 16.41% of the diagnosed prevalent cases of COPD were in GOLD Stage I, 24.66% were in GOLD Stage II, 29.09% were in GOLD Stage III, and 29.84% were in GOLD Stage IV. GlobalData epidemiologists estimated that 18,065,499 of the diagnosed prevalent cases of COPD in 2013 would have survived to the end of the year.

This analysis for COPD is a market-driven epidemiological report providing detailed segmentations of the COPD patient population, including the age- and sex-specific distribution of the total and diagnosed prevalent cases, the GOLD stage distributions for the total and diagnosed prevalent cases, the diagnosed prevalent cases that have comorbidities, and an estimation of the exacerbations and mortality for the forecast COPD patients. GlobalData epidemiologists also describe in detail the sources and methodology that were used in the forecast, thereby ensuring transparency of the forecasting process.

Scope

- The Chronic Obstructive Pulmonary Disease (COPD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for COPD in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast of the total prevalent cases of COPD and total diagnosed prevalent cases of COPD, segmented by age and sex. Additionally it provides segmentation of diagnosed prevalent cases by severity using the GOLD standard.
- The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The COPD EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global COPD market.
- Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for COPD therapeutics in each of the markets covered.
- Identify the COPD comorbidities that are most important to your marketing plans

Contents:

1.1 List of Tables

1.2 List of Figures

2 Introduction
4 Appendix

4.1 Bibliography

4.2 Physicians and Specialists Included in this Study

4.3 About the Authors

4.3.1 Epidemiologists

4.3.2 Reviewers

4.3.3 Global Director of Therapy Analysis and Epidemiology

4.3.4 Global Head of Healthcare

4.4 About Us

4.5 About EpiCast

4.6 Disclaimer

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for COPD

Table 2: GOLD COPD Severity Diagnostic Criteria

Table 3: 8MM, Sources Used to Forecast the Total Prevalent Cases of COPD

Table 4: 8MM, Sources Used to Determine the Severity Segmentation Among the Total Prevalent Cases of COPD

Table 5: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD Via the Diagnosis Rate

Table 6: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD Via the Diagnosed Prevalence Rate

Table 7: 8MM, Sources Used to Forecast the Prevalent Cases of Comorbidities Among the Diagnosed Prevalent Cases of COPD

Table 8: 8MM, Sources Used to Forecast the GOLD Severity Among the Diagnosed Prevalent Cases of COPD

Table 9: 8MM, Sources Used to Forecast the Exacerbations and Mortality Among the Diagnosed Prevalent Cases of COPD by the GOLD Stage

Table 10: 8MM, Total Prevalent Cases of COPD, Both Sexes, Ages =35 Years, N, Selected Years, 2013-2023

Table 11: 8MM, Age-Specific Total Prevalent Cases of COPD, Both Sexes, N (Row %), 2013

Table 12: 8MM: Sex-Specific Total Prevalent Cases of COPD, Ages =35 Years, N (Row %), 2013

Table 13: 8MM, Total Prevalent Cases of COPD by the GOLD Severity Stage, Both Sexes, Ages =35 Years, N (Row %), 2013

Table 14: 8MM, Diagnosed Prevalent Cases of COPD, Both Sexes, Ages =35 Years, N, Selected Years, 2013-2023

Table 15: 8MM, Age-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N (Row %), 2013

Table 16: 8MM: Sex-Specific Diagnosed Prevalent Cases of COPD, Ages =35 Years, N (Row %), 2013

Table 17: 8MM, Diagnosed Prevalent Cases of COPD by the GOLD Severity Stage, Both Sexes, Ages =35 Years,
Table 18: 8MM, Comorbidities Among the Diagnosed Prevalent Cases of COPD, Both Sexes, Ages =35 Years, N, 2013

Table 19: 8MM, Diagnosed Prevalent COPD Cases Experiencing Exacerbations and Mortality, Both Sexes, Ages =35, N, 2013

1.2 List of Figures

Figure 1: 8MM, Forecast Methodology Case Flow Overview

Figure 2: 8MM, Total Prevalent Cases of COPD, Both Sexes, Ages =35 Years, N, Selected Years, 2013-2023

Figure 3: 8MM, Age-Specific Total Prevalent Cases of COPD, Both Sexes, N, 2013

Figure 4: 8MM, Sex-Specific Total Prevalent Cases of COPD, Ages =35 Years, N, 2013

Figure 5: 8MM, Age-Standardized Total Prevalence of COPD (%), 2013

Figure 6: 8MM, Diagnosed Prevalent Cases of COPD, Both Sexes, Ages =35 Years, N, Selected Years, 2013-2023

Figure 7: 8MM, Age-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N (Row %), 2013

Figure 8: 8MM, Sex-Specific Diagnosed Prevalent Cases of COPD, Ages =35 Years, 2013

Figure 9: 8MM, Age-Standardized Diagnosed Prevalence of COPD (%), Both Sexes, Ages =35 Years, 2013

Figure 10: 8MM, Diagnosed Prevalent COPD Cases Experiencing Mortality, Both Sexes, Ages =35 Years, N, 2013

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3517580/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
Web Address: http://www.researchandmarkets.com/reports/3517580/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 3995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 7990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 11985</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________________________ Last Name: _______________________________________
Email Address: * _______________________________________
Job Title: ___________________________________________
Organisation: _________________________________________
Address: ___________________________________________
City: _______________________________________________
Postal / Zip Code: ___________________________________
Country: ___________________________________________
Phone Number: _______________________________________
Fax Number: _________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ___________________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World